- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02744508
Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery
June 19, 2018 updated by: Yonsei University
Postoperative nausea and vomiting (PONV) is related with extended hospital day and risk factor of aspiration pneumonia.
Postoperative patient controlled intravenous analgesia is related with postoperative nausea and vomiting.
Selective 5-HT3 antagonist, Palonosetron, is the most recent medication for prevention of PONV.
Purpose of our study is comparison of PONV preventive effect of palonosetron and combination of palonosetron and dexamethasone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
202
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients who are undergoing minor orthopedic surgery.
- IV patient controlled analgesia
Exclusion Criteria:
- 1. minority (0~19 year)
- patients who are belongs to ASA class 3 or more, and have underlying complicated cardiovascular or psychological disease.
- Steroid medication
- Diabetes Mellitus medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: P group
Palonosetron group
|
|
|
Experimental: PD group
Palonosetron and dexamethasone group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
incidence of clinically significant PONV with PONV impact scale
Time Frame: 72 hours
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 24, 2015
Primary Completion (Actual)
March 20, 2017
Study Completion (Actual)
March 20, 2017
Study Registration Dates
First Submitted
April 18, 2016
First Submitted That Met QC Criteria
April 18, 2016
First Posted (Estimate)
April 20, 2016
Study Record Updates
Last Update Posted (Actual)
June 20, 2018
Last Update Submitted That Met QC Criteria
June 19, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Serotonin Agents
- Serotonin Antagonists
- Serotonin 5-HT3 Receptor Antagonists
- Dexamethasone
- Palonosetron
Other Study ID Numbers
- 4-2015-0232
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Orthopedic Surgery
-
Rigshospitalet, DenmarkThe Danish Medical Research Council; Oberstinde Kirsten Jensa la Cours FoundationCompleted
-
University Hospital, GrenobleCompletedOrthopedic SurgeryFrance
-
Centre Hospitalier Universitaire de Saint EtienneCompletedOrthopedic SurgeryFrance
-
Yonsei UniversityUnknownOrthopedic Surgery-lower Leg SurgeryKorea, Republic of
-
University Hospital, LimogesCompleted
-
University Hospital, MontpellierCompleted
-
Groupe Hospitalier Paris Saint JosephWithdrawn
-
University Hospital, MontpellierUnknownOrthopedic SurgeryFrance
-
[Redacted]3M; Solventum US LLCWithheldAbdominal Surgery | Orthopedic Surgery | Vascular Surgery | Cardiovascular SurgeryUnited States
-
Yonsei UniversityRecruitingOrthopedic SurgeryKorea, Republic of
Clinical Trials on palonosetron
-
Seoul National University Bundang HospitalRecruiting
-
Incheon St.Mary's HospitalUnknownPostoperative Nausea and VomitingKorea, Republic of
-
Xiamen LP Pharmaceutical Co., LtdCompletedNausea With Vomiting Chemotherapy-InducedUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Xiamen LP Pharmaceutical Co., LtdRecruitingChemotherapy-induced Nausea and VomitingUnited States
-
Fujian Shengdi Pharmaceutical Co., Ltd.CompletedNausea and Vomiting Associated With Moderate Emetic Risk Anticancer AgentsChina
-
Consorzio OncotechCompletedNEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer (GIM15-NEPA)Chemotherapy-induced Nausea and Vomiting
-
Helsinn Healthcare SACompletedPostoperative Nausea and VomitingRussian Federation, Ukraine
-
Zhuhai Beihai Biotech Co., LtdNot yet recruiting
-
University Hospital, BordeauxBordeaux Association for Training and Research in Obstetric Gynecology; Association...CompletedHyperfibrinolysis | Postpartum HemorrhageFrance